Loading

Menlo Therapeutics Inc. is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with various conditions. PRIVACY STATEMENT

Science Behind Serlopitant

Serlopitant, a highly selective, once-daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK1R, is an investigational drug that acts through a novel mechanism to potentially alleviate pruritus associated with various conditions.

Pipeline of Indications

Development Programs at Menlo Therapeutics with Serlopitant

Development Programs at Menlo Therapeutics with Serlopitant